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IFCC, International Federation of Clinical Chemistry and Laboratory Medicine; RMP, 
 
 
26  reference measurement procedure; IDF, International Diabetes Federation; EASD, 
 
 
27  European Association for the Study of Diabetes; ADA, American Diabetes 
 
 
28  Association; QTmodel, IFCC Model for Quality Targets; C-EUBD, Committee 
 
 
29  Education in the Use of Biomarkers in Diabetes; EQA, external quality assessment; 
 
 
30  PT, proficiency testing; EurA1c, European HbA1c trial; fresh whole blood (WB); 
 
 
31  lyophilized hemolysate (LH); NGSP, National Glycohemoglobin Standardization 
 
 
32  
 
 
33  
Program; BLCV, between laboratory coefficient of variation. 
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Abstract 
 
 
36  BACKGROUND: A major objective of the IFCC Committee on Education and Use of 
 
 
37  Biomarkers in Diabetes is to generate awareness and improvement of HbA1c assays 
 
 
38  
 
 
39  
through evaluation of the performance in countries and manufacturers. 
 
 
40  METHODS: Fresh whole blood and lyophilized hemolysate specimens manufactured 
 
 
41  from the same pool were used by 17 EQA organizers to evaluate analytical 
 
 
42  performance of 2166 laboratories. Results were evaluated per country, per 
 
 
43  manufacturer, and per manufacturer and country combined according to criteria of 
 
 
44  
 
 
45  
the IFCC model for Quality targets. 
 
 
46  RESULTS: At the country level with fresh whole blood specimens, 6 countries met 
 
 
47  the IFCC criterion, 2 did not, and 2 were borderline. With lyophilized hemolysates, 5 
 
 
48  countries met the criterion, 2 did not, and 3 were borderline. At the manufacturer level 
 
 
49  using fresh whole blood specimens, 13 manufacturers met the criterion, 8 did not, 
 
 
50  and 3 were borderline. Using lyophilized hemolysates, 7 manufacturers met the 
 
 
51  criterion, 6 did not, and 3 were borderline. In both country and manufacturer groups 
 
 
52  the major contribution to total error derived from between laboratory variation. There 
 
 
53  were no substantial differences in performance between groups using fresh whole 
 
 
54  
 
 
55  
blood or lyophilized hemolysate samples. 
 
 
56  CONCLUSION: The state of the art is that 1 out of 20 laboratories does not meet the 
 
 
57  IFCC criterion but there are substantial differences between country and between 
 
 
58  manufacturer groups. Efforts to further improve quality should focus on reducing 
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59  
 
between laboratory variation. With some limitations, fresh whole blood and well- 
 
 
60  
 
 
61  
 
 
62  
defined lyophilized specimens are suitable for purpose. 
 
 
63  
 
 
64  
Introduction 
 
 
65  HbA1c is a key parameter in the monitoring of diabetic control as well as in the 
 
 
66  screening and diagnosis of Type 2 diabetes (1,2). The high clinical relevance of 
 
 
67  HbA1c testing necessitates high quality measurement. This is well recognized by the 
 
 
68  International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), which 
 
 
69  
 
 
70  
 
 
71  
has a long standing program to improve HbA1c testing: 
 
 The development of the IFCC Reference Measurement Procedure (RMP) by the 
IFCC Working Group on Standardization of HbA1c (3). The working group 
72  embedded the RMP in a sustainable global network of 15 approved network 
 
 
73  
 
 
74  
 
 
75  
laboratories (4). 
 
 A consensus statement from the International Diabetes Federation (IDF), 
European Association for the Study of Diabetes (EASD), American Diabetes 
76  Association (ADA) and the IFCC which recognized the RMP as the only valid 
 
 
77  
 
 
78  
 
 
79  
 
 
80  
 
 
81  
analytical anchor to standardize HbA1c (5). 
 
 Subsequent to the working group an IFCC Task Force on Implementation of 
HbA1c Standardization developed a model for Quality Targets (QTmodel) (6). 
 More recently the IFCC Committee on Education and Use of Biomarkers in 
Diabetes (C-EUBD) has a focus on education around the use of biomarkers for 
82  diabetes, encompassing both the analytical and clinical utility of HbA1c (7). 
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83  
 
External Quality Assessment (EQA)/Proficiency Testing (PT) is a powerful 
 
 
84  educational tool to monitor quality which, by identifying poor performing laboratories 
 
 
85  and test systems, can be used as a tool to improve quality. Smaller scale studies 
 
 
86  initially in Italy and later in a multinational project in Germany, Belgium and the 
 
 
87  Netherlands were used as a basis for the design of the current study by the C-EUBD 
 
 
88  (8,9). 17 EQA organizers in Europe agreed to participate in the European HbA1c 
 
 
89  Trial (EurA1c). Half of the EQA organizers preferred to use fresh whole blood 
 
 
90  samples (WB) and the other half lyophilized hemolysates (LH). This paper relates to 
 
 
91  the EQA results in both matrices and are considered per country, per manufacturer 
 
 
92  
 
 
93  
 
 
94  
and per manufacturer and country combined. 
 
 
95  
 
 
96  
Materials and Methods 
 
 
97  Study Design 
 
 
98  The EurA1c study design is shown in Fig.1. From two pools of fresh whole blood 
 
 
99  (yellow), batches of WB (green) and LH EQA specimens were prepared. Specimens 
 
 
100  were shipped in bulk to the EQA organizers who forwarded them to their participants. 
 
 
101  Results were collected and evaluated (blue). The study also included frozen whole 
 
 
102  blood specimens (the common sample in IFCC and NGSP certification). 
 
 
103  Homogeneity and stability were tested according to ISO 13528 and results met the 
 
 
104  criteria. Frozen samples, homogeneity, stability and targeting (all grey) were beyond 
 
 
105  
 
 
106  
the scope of this paper and will not be addressed. 
 
 
107  Sample preparation and assigned values 
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108  250 mL donations of whole blood were collected into EDTA from diabetic and non- 
 
109  diabetic volunteers and used to make two pools (EurA1c-1 and EurA1c-2). Target 
 
110  values were assigned with the RMP by 5 approved network laboratories; each 
 
111  laboratory measured the samples in fourfold. The assigned value for EurA1c-1 was 
 
112  42.3 (6.02%) with an expanded uncertainty of 0.7 mmol/mol (0.06%). The assigned 
 
113  value for EurA1c-2 was 57.9 mmol/mol (7.45%) with an expanded uncertainty of 0.9 
 
114  mmol/mol (0.08%). From each pool WB and LH specimens were made. Throughout 
 
115  the paper IFCC- and National Glycohemoglobin Standardization Program (NGSP) 
 
116  units will be referred to with results in NGSP units in brackets. 
 
117  
 
 
118  Logistics 
 
119  In order to process the samples in a timely manner, donations were collected on day 
 
120  one, on day two the WB samples were shipped by courier to the respective EQA 
 
121  organizers at ambient temperature. On day three the EQA organizers distributed the 
 
122  samples to participants, again at ambient temperature, who analyzed the samples on 
 
123  day four or five. An exception to this was the samples for Italy which were shipped 
 
124  direct to the participating laboratories on cool packs. LH samples were manufactured 
 
125  the day after blood donation; shipment and analysis was between November 2016 
 
126  and April 2017. 
 
127  
 
 
128  Data Collection and Evaluation 
 
129  EQA organizers collated the results from their participants and forwarded them to the 
 
130  IFCC network coordinator. The number of laboratories (2166) is the number of 
 
131  submitted datasets. The number of manufacturers (24) is the number of platforms 
 
132  that could be evaluated reasonably (N>5) according to the QTmodel. Mean values, 
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133  between laboratory CVs and bias were calculated, after removal of outliers, defined 
 
134  as a value outside the target  25%. Outliers amounted to 1% of all results. 
 
135  Commonly these outliers were due to mix-up of samples or decimal errors. IFCC 
 
136  results were converted to NGSP units with the Master Equation (NGSP = 
 
137  0.0915IFCC + 2.15). (10) 
 
138  The bias is defined as {(M1-T1) + (M2 –T2)}/2 in which M1 and M2 are the mean 
 
139  measured HbA1c concentrations in samples 1 and 2, and T1 and T2 are the target 
 
140  values of samples 1 and 2 assigned with the RMP. The between laboratory CV 
 
141  (BLCV) is defined as the mean of the BLCV in samples 1 and 2. Note that the BLCV 
 
142  in IFCC and NGSP units differs substantially; for explanation see Ref 11. 
 
143  
 
 
144  Manufacturers/Instruments 
 
145  The study aimed to capture all manufacturer details but unfortunately registration was 
 
146  different per EQA organizer. For Siemens point-of-care users the DCA 2000 and 
 
147  Vantage instruments were combined to one group. The Menarini/ARKRAY 8160 VP 
 
148  and TP instruments formed a single group as did the various types of Bio-Rad 
 
149  Variant. There was a considerable variation in reporting method type for Roche 
 
150  methods, therefore these were combined into one group as they all used the same 
 
151  method principle.137 laboratories did not report their instrument at all; results of this 
 
152  group were included in the calculation per country and in the result per manufacturer 
 
153  they are considered as a separate group. 
 
154  
 
 
155  IFCC Model for Quality Targets 
 
156  EurA1c results were evaluated according to the criteria of the QTmodel. Although 
 
157  previously described in the literature a short explanation of the model follows to 
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158  facilitate the reader in understanding the Figures (6,12).The QTmodel is based on the 
 
159  concept of total error which takes into account the principal sources of analytical 
 
160  error: bias and imprecision. Performance criteria are derived from sigma metrics. 
 
161  Bias is plotted on the vertical axis with scaling in IFCC units (mmol/mol) and NGSP 
 
162  units (% in parentheses). Imprecision, expressed as the Coefficient of Variation (CV) 
 
163  is plotted on the horizontal axis. The criterion was set at 5 mmol/mol (0.46%) at the 2 
 
164  sigma level and applies to HbA1c concentrations around 50 mmol/mol (6.7%). In the 
 
165  graph this criterion is shown as the line drawn from 5 mmol/mol (0.46%) on the 
 
166  vertical axis to 5.0% (3.4%) on the horizontal axis. A performance within the triangle 
 
167  meets the criterion. When HbA1c is used for diagnosis more stringent criteria might 
 
168  be desirable. Therefore more challenging criteria are defined at total allowable errors 
 
169  of 3.3, 2.2 and 1.1 mmol/mol (0.3-0.2 and 0.1%), represented by the bronze, silver 
 
170  and gold triangles in the QTmodel. The QTmodel can be applied at the level of a 
 
171  single laboratory (precision is the within laboratory CV) or for groups of laboratories 
 
172  (precision is the between laboratory CV). The latter is used in this paper to evaluate 
 
173  the performance of specific country/manufacturer groups. 
 
174  
 
 
175  
 
 
176  Results 
 
177  
 
 
178  Preamble 
 
179  The EurA1c Trial revealed many data: results of 2166 laboratories provided by 17 
 
180  EQA organizers and measured with assays of 41 different manufacturers. In addition 
 
181  there were two matrices and according to the consensus statement results have to 
 
182  be reported in IFCC- and NGSP units. The multiple and detailed data necessitated 
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183  choices on what and how to present results. Condensed EQA results in WB and LH 
 
 
184  are included in the main body of the paper and the detailed data are systematically 
 
 
185  
 
 
186  
presented in the supplemental data section. 
 
 
187  Results by Country 
 
 
188  Table 1 shows the results ranked alphabetically by country. The first two columns 
 
 
189  show the names and countries of the EQA organizers. Then there are sections with 
 
 
190  results in WB and LH. For each matrix there are columns for the number of 
 
 
191  laboratories (n), bias and between laboratory CV in IFCC- and NGSP units 
 
 
192  
 
 
193  
respectively. Results are the mean of both samples EurA1c-1 and EurA1c-2. 
 
 
194  Results by Manufacturer 
 
 
195  Table 2 shows the results ranked alphabetically by manufacturer. The first column 
 
 
196  shows the manufacturer. Then there are sections with results in WB and LH. For 
 
 
197  each matrix there are columns for the number of laboratories (n), bias and between 
 
 
198  laboratory CV in IFCC- and NGSP units. Results are the mean of both samples 
 
 
199  
 
 
200  
EurA1c-1 and EurA1c-2. 
 
 
201  Performance of each Country in the QTmodel 
 
 
202  Fig. 2A and B show the performances by country in WB and LH in the framework of 
 
 
203  
 
 
204  
the criteria of the QTmodel. The plotted bias and BLCV were taken from table 1. 
 
 
205  Performance of each Manufacturer in the QTmodel 
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206  
 
Fig. 2C and D show the performance of each manufacturer in WB and LH in the 
 
 
207  framework of the criteria of the QT model. The plotted bias and BLCV were taken 
 
 
208  
 
 
209  
from table 2. 
 
 
210  Manufacturer performance by Country in the QTmodel 
 
 
211  Fig. 3 shows the performance of each manufacturer by country within the framework 
 
 
212  of the QTmodel. Scaling is omitted to simplify. There were more than 200 
 
 
213  manufacturer/country combinations, therefore only data for combinations with at least 
 
 
214  5 laboratories per manufacturer in a country are calculated. This resulted in 79 such 
 
 
215  combinations (data in tables 4,8,12,16 of the supplemental data). Fig. 3 shows the 
 
 
216  QTmodel plots for manufacturers with at least 6 laboratories using their test in at 
 
 
217  least 4 countries. Four manufacturers are included for both WB and LH and three for 
 
 
218  
 
 
219  
WB only. 
 
 
220  Detailed results in supplemental data 
 
 
221  Detailed results are provided in the supplemental data. Table 3 shows how the data 
 
 
222  are systematically differentiated and organized in the 16 supplemental tables. For 
 
 
223  example: Supplemental table 2 shows the results per sample in IFCC units in WB for 
 
 
224  
 
 
225  
 
 
226  
manufacturers with more than 5 laboratories using their assay. 
 
 
227  
 
 
228  
Discussion 
 
 
229  Overall performance 
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230  The last line of table 1 shows the overall performance of all participating laboratories. 
 
231  In the group of laboratories that used WB the mean overall bias of 1517 laboratories 
 
232  was +0.2 mmol/mol (+0.02%) and the BLCV was 4.4% (3.0%). In the group of 
 
233  laboratories that used LH the mean bias of 649 laboratories was -0.5 mmol/mol (- 
 
234  0.05%) and the BLCV was 4.9% (3.2%). These data are plotted in the QTmodel in 
 
235  Fig. 2 A and B (black stars). It can be seen that the performance in WB is borderline 
 
236  within and in LH borderline outside the criterion. The overall performance data can be 
 
237  interpreted as, in both matrices, approximately 95% of the laboratories meet the 
 
238  criterion of a total allowable error below 5 mmol/mol (0.46%). The position of the 
 
239  black stars is close to the horizontal and not to the vertical axis, implying that the 
 
240  major contribution to the total error is derived from the BLCV rather than bias. A 
 
241  similar performance pattern has been reported by the College of American 
 
242  pathologists (CAP) survey in the US (13). 
 
243  
 
 
244  Per Country 
 
245  In table 1 the performance data is split by country. In WB blood the bias ranges from 
 
246  0.0 mmol/mol (0.0%) in Sweden and Turkey to +0.8 mmol/mol (+0.08%) in Italy. The 
 
247  BLCV ranges from 3.0% (2.0%) in Ireland to 7.2% (4.8%) in Turkey. In LH bias 
 
248  ranges from 0.0 mmol/mol (0.0%) in Greece to -1.2 mmol/mol (-0.11%) in South 
 
249  Africa (2 laboratories). The between laboratory CV ranges from 3.1% (2.1%) in Italy 
 
250  to 6.4% (4.2%) in Greece. The data are plotted in the QTmodel in Fig 2 A and B. 
 
251  There are substantial differences in performance per country. The best performing 
 
252  countries are approaching the bronze performance criterion line (Ireland in WB; Italy 
 
253  in LH) whereas other countries are outside the 2 sigma criterion (Turkey and 
 
254  Switzerland in WB; Greece and Austria in LH). In other words: the total error in the 
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255  best performing countries (approximately 3 mmol/mol; 0.27%) is half of the total error 
 
256  in countries with the poorest performance. 
 
257  
 
 
258  A remarkable phenomenon was observed in Austria: the 11 laboratories using the 
 
259  Abbott enzymatic test had an excellent BLCV of 2.6% (1.8%) but a high bias of -5.8 
 
260  mmol/mol (-0.53%; tables 8 and 16 supplemental data). This led to suspicion of a 
 
261  matrix effect with the LH samples. However no difference in results with WB or LH 
 
262  was seen when samples were measured with the Abbott enzymatic test at the IFCC 
 
263  Reference laboratory (results not shown). This suggests a specific standardization 
 
264  issue with the Abbott assay in Austria. When the results of the 11 labs were omitted 
 
265  from of the calculations for Austria, bias and BLCV dropped substantially and the 
 
266  overall Austrian performance moved from outside the criterion (AT in Fig. 2B) to 
 
267  within the criterion (A* in Fig. 2B). 
 
268  The data points representing the respective countries are all close to the horizontal 
 
269  and distant from the vertical axis. Thus, like for the overall performance, traceability 
 
270  to the IFCC RMP is achieved in all countries and remaining total error stems mainly 
 
271  from between laboratory variation. 
 
272  
 
 
273  Per Manufacturer 
 
274  Detailed results per manufacturer are in the supplemental data and divided into 
 
275  results of manufacturers with 6 or more laboratories (n = 40; tables 2,6,10,14) and 
 
276  manufacturers with less than 6 laboratories (n = 29; tables 3,7,11,15). In the small 
 
277  groups relevant conclusions can not be made and therefore only the condensed data 
 
278  of manufacturers with 6 or more laboratories are shown in Table 2 and Fig. 2. Fig. 2 
 
279  C and D show that there are substantial differences between manufacturers. 
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280  Excellent performance is seen with WB (A) and LH (H) but there are also poor 
 
281  performers (S and K in WB; T and A in LH). In general the data points for the 
 
282  manufacturers are quite close to the horizontal and distant from the vertical axis. 
 
283  From this it can be concluded that the majority of manufacturers achieved traceability 
 
284  to the IFCC RMP. Total error at the manufacturer level mainly came from between 
 
285  laboratory variation. 
 
286  
 
 
287  By Manufacturer and by Country 
 
288  Fig. 3 shows the performance per manufacturer per country for manufacturers with at 
 
289  least 6 laboratories using their test in at least 4 countries. For some manufacturers 
 
290  the data points are close to each other which implies that performance in the 
 
291  countries is similar (Fig. 3G and 3F). However for Roche using WB there are 
 
292  differences between the countries: good results in Sweden, the Netherlands and UK 
 
293  and quite poor in Switzerland and Turkey (Fig. 3C2). Differences between countries 
 
294  for the assay of a manufacturer can be laboratory based and be related to 
 
295  maintenance, rigidity of quality management or training/motivation of the staff. They 
 
296  can also be manufacturer based and be related to training and education of the 
 
297  customers and batch-to-batch management of calibrators and reagents. Like in the 
 
298  previous sections the major contribution to total error derived from between 
 
299  laboratory variation. 
 
300  
 
 
301  Fresh Whole Blood and Lyophilized Hemolysate 
 
302  In the EurA1c trial both WB and LH were used. In principle WB is the ideal sample: it 
 
303  is patient material and thus commutable per definition, but sample stability limits its 
 
304  use. General ageing causes lysis, glucose consumption by erythrocytes (formation of 
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305  lactic acid lowers pH), spectral changes (browning) and additional hemoglobin 
 
306  fractions. Glycation (HbA1c formation) may proceed during storage. Ageing 
 
307  processes mean that WB is a dynamic specimen that may change characteristics 
 
308  over time depending on shipment time and temperature, resulting in different 
 
309  properties from laboratory to laboratory over wide geographical areas with differing 
 
310  infrastructures and thus different HbA1c results. Results of Italian laboratories in WB 
 
311  are slightly higher than in other countries. This may reflect differences in shipment 
 
312  temperature (Italian samples were shipped on cool packs). It is not clear if the 
 
313  difference is significant at all, and if yes, if there is a negative impact on shipment on 
 
314  cool packs (increased lysis) or at ambient temperature (ageing). LH does not have 
 
315  stability problems but may have commutability issues. Before lysis plasma is 
 
316  removed and cell-debris is removed. The reconstitution volume is such as that the 
 
317  hemoglobin concentration is equal to WB but matrix changes may have an impact. It 
 
318  is assumed that LH may not be commutable with the Roche assays. However, 
 
319  EurA1c results (bias in WB -0.9 mmol/mol/0.08%; bias in LH -0.1 mmol/mol/0.01%) 
 
320  show only a small difference between the matrices and it is not clear whether this 
 
321  difference derives from non-commutability of LH or from instability of WB blood. 
 
322  Lyophilized material is not suitable for (point of care) methods that can only work with 
 
323  whole blood. Inappropriate reconstitution may also cause complications. It must be 
 
324  taken into account that the manufacture of LH, in general, – and thus the 
 
325  commutability- varies widely per manufacturer (use of cryolyoprotectants and 
 
326  native/artificial HbA1c). In summary: with WB samples there is doubt around sample 
 
327  stability and with LH there is doubt around commutability. The EurA1c trial showed 
 
328  that bias and BLCV are comparable for both matrices. Probably the impact of 
 
329  instability of WB and non-commutability of LH is low but it should be stressed that this 
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330  is only true for the specimens and test conditions in this study. With knowledge of the 
 
331  limitations and in the proper setting, both WB and LH are suitable for EQA purposes. 
 
332  EQA organizers balance the advantages and disadvantages of both sample types. In 
 
333  countries with fast and reliable communication links where the whole logistic chain of 
 
334  blood donation, dispensing/packaging of the samples, shipment and measurement in 
 
335  the laboratories is feasible within one working week WB is the specimen of choice. In 
 
336  countries where this is not possible, LH will be used. 
 
337  
 
 
338  State of the art 
 
339  The EurA1c results show that the present state of art of HbA1c measurement in 
 
340  relation to quality targets can be summarized in one number: a total error of 
 
341  approximately 5 mmol/mol (0.46%). In words: if HbA1c of a patient is measured in 
 
342  one of the 2166 laboratories that participated in the EurA1c trial, it can be expected 
 
343  that 1 out of 20 laboratories will report a result that will differ 5 mmol/mol (0.46%) or 
 
344  more from the true value. 
 
345  Results have shown that the major contribution to total error was derived from the 
 
346  between laboratory variation. The low bias observed suggests that the main 
 
347  manufacturers have made significant improvements in the calibration of their 
 
348  instruments to align with the consensus statement, which dictates the use of the 
 
349  IFCC RMP. To achieve further improvement, the focus should be on reducing the 
 
350  between laboratory variation. A starting point for such improvement is knowledge of 
 
351  the causes. The EurA1c trial attempted to elicit some of these causes by 
 
352  investigation of a number of factors. Figures 2 and 3 show that there are substantial 
 
353  differences: between countries and between manufacturers. In addition the 
 
354  performance of laboratories using the test of the same manufacturer can be (but is 
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355  not always) quite different per country. The data do not allow a clear conclusion on 
 
356  the cause of poor performance. One can speculate that it is a combination of factors. 
 
357  Due to e.g. financial pressure, quality may have a different priority. In case of low 
 
358  priority, the attitude of the laboratories towards quality will be lower. 
 
359  
 
 
360  Clinical considerations 
 
361  The quality target in the QTmodel is a total allowable error of 5 mmol/mol (0.46%). 
 
362  Thus if the true value is 43 mmol/mol (6.1%) results between 38 and 48 mmol/mol 
 
363  (5.6 to 6.5%) are acceptable. One can argue that an error of 5 mmol/mol (0.46%) is 
 
364  good enough for monitoring of diabetic control, but questionable for diagnosis: the 
 
365  clinical interpretation of 38 or 48 mmol/mol (5.6/6.5%) is quite different. The 
 
366  community of laboratory medicine should aim for a tighter quality goal, closer to the 
 
367  “bronze” target of 3.3 mmol/mol (0.30%) in the QTmodel. 
 
368  
 
 
369  Strengths and Weaknesses 
 
370  The strengths of EurA1c include the scale, rigour and quality of the study with 
 
371  international oversight from the C-EUBD resulting in an overview of the state of the 
 
372  art of HbA1c measurement with comparisons between countries and manufacturers. 
 
373  However there are also weaknesses. A weak point is that a number of laboratories 
 
374  did not report their method (group “unknown”) and that EQA organizers have different 
 
375  definitions of the same method. Striking examples are the tests of Roche: definitions 
 
376  are “instrument type”, “generation 2 or 3 reagent”, “whole blood/hemolysate mode” or 
 
377  simply “Roche Tina-quant”. The approach of the EurA1c evaluation was to consider 
 
378  all Roche results as one group, whilst not ideal the differentiation into all variables 
 
379  would reveal 16 Roche methods which is not ideal either. 
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380  
 
 
381  
 
 
382  Conclusions 
 
 
383  A trial like EurA1c with collaboration of many EQA organizers was possible. With 
 
 
384  some limitations, WB specimens and well-defined LH appeared suitable for purpose. 
 
 
385  The state of the art was a total error of 5 mmol/mol at the 2 sigma level. 
 
 
386  Differentiation of the results showed substantial differences between countries and 
 
 
387  between manufacturers. Traceability to the IFCC RMP was a minor issue; total error 
 
 
388  derived mainly from between laboratory variation. International studies like EurA1c 
 
 
389  trigger all parties involved in HbA1c measurement to consider and improve quality 
 
 
390  and thus to work on better patient care. Therefore the IFCC C-EUBD will continue to 
 
 
391  organize the trial yearly. EurA1c has Eurocentric roots but participation is open to 
 
 
392  
 
 
393  
 
 
394  
non-European countries. 
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513  Table 1. EQA/PT organizers in the EurA1c project and summary per country of number of participating labs, bias, and between 
514  laboratory CV in fresh whole blood and lyophilized hemolysates. 
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* Individual laboratories of a number of countries 
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Country 
 
Organisation 
 
Fresh Whole Blood 
 
Lyophilized Hemolysate 
  
n 
IFCC 
Bias in mmol/mol 
(Between Lab CV) 
NGSP 
Bias in % 
(Between Lab CV) 
 
n 
IFCC 
Bias in mmol/mol 
(Between Lab CV) 
NGSP 
Bias in % 
(Between Lab CV) 
Austria 
 
ÖQUASTA    107 -1.0 (5.3%) -0.09 (3.6%) 
139 +0.4 (3.2%) +0.04 (2.1%)    Belgium 
 
WIV-ISP 
   70 -0.4 (5.3%) -0.04 (3.6%) Czech Republic 
 
SEKK 
135 +0.3 (3.6%) +0.03 (2.4%) 132 -0.8 (4.6%) -0.07 (3.1%) France 
 
Biologie Prospective 
652 -0.2 (4.8%) -0.02 (3.2%)    Germany 
 
INSTAND e.V. 
   73 0.0 (6.4%) 0.00 (4.2%) Greece 
 
ESEAP 
   54 -0.4 (4.9%) -0.04 (3.3%) International* 
 
ERL 
30 +0.2 (3.0%) +0.02 (2.0%)    Ireland 
 
IEQAS 
84 +0.8 (4.5%) +0.08 (3.0%) 48 -0.2 (3.1%) -0.02 (2.1%) Italy 
 
Centro di Ricerca Biomedica 
136 +0.2 (3.4%) +0.02 (2.2%)    Netherlands 
 
SKML 
   43 -0.5 (3.8%) -0.05 (2.6%) Portugal 
 
Inst. Nac. de Saude Dr. Ricardo Jorge 
   2 -1.2 (4.1%) -0.11 (2.7%) South Africa 
 
Tygerberg Hospital 
   76 -0.5 (3.3%) -0.05 (2.2%) Spain 
 
SEQC-ML 
117 0.0 (3.4%) 0.00 (2.3%)    Sweden 
 
EQUALIS 
29 +0.4 (5.8%) +0.04 (3.9%)    Switzerland 
 
MQ 
48 0.0 (7.2%) 0.00 (4.8%) 45 -0.2 (5.2%) -0.02 (3.5%) Turkey 
 
TUBITAK UME 
148 +0.6 (3.5%) +0.06 (2.4%)    United Kingdom 
 
WEQAS 
      
 
 
 
1517 +0.2 (4.4%) +0.02 (3.0%) 649 -0.5 (4.9%) -0.05 (3.2%) Overall  
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Table 2. Summary per manufacturer of number of participating labs, bias, and between laboratory CV in fresh whole blood and 
lyophilized hemolysates. 
 
 
Manufacturer Fresh Whole Blood Lyophilized Hemolysate 
 
n 
IFCC 
Bias in mmol/mol 
(Between Lab CV) 
NGSP 
Bias in % 
(Between Lab CV) 
 
n 
IFCC 
Bias in mmol/mol 
(Between Lab CV) 
NGSP 
Bias in % 
(Between Lab CV) 
Abbott Architect Enzymatic 
 
Abbott Architect Immuno 
21 
6 
-0.1 
-1.8 
(1.6%) 
(4.0%) 
-0.01 
-0.16 
(1.1%) 
(2.8%) 
24 -4.0 (6.0%) -0.37 (4.0%) 
 
Abbott Other 
Alere Afinion 
Beckman Coulter AU 
Beckman Coulter UC DxC 
Bio-Rad D10 
6 
76 
26 
15 
53 
+1.9 
-0.7 
-0.6 
-1.0 
+0.8 
(4.6%) 
(3.4%) 
(5.6%) 
(3.5%) 
(4.8%) 
+0.18 
-0.06 
-0.06 
-0.10 
+0.07 
(3.0%) 
(2.2%) 
(3.8%) 
(2.4%) 
(3.2%) 
 
 
7 
 
37 
 
 
+1.6 
 
-1.2 
 
 
(6.5%) 
 
(5.2%) 
 
 
+0.15 
 
-0.11 
 
 
(4.4%) 
 
(3.5%) 
 
Bio-Rad D 100 
Bio-Rad Variant 
Medinor 
11 
86 
6 
-0.8 
+0.9 
-4.7* 
(1.8%) 
(4.0%) 
(14.6%) 
-0.08 
+0.08 
-0.43 
(1.2%) 
(2.6%) 
(9.9%) 
16 
38 
-0.3 
+1.3 
(1.9%) 
(4.8%) 
-0.03 
+0.12 
(1.2%) 
(3.2%) 
 
Menarini HA-8160 
Menarini HA-8180 
 
91 
82 
+0.4 
+0.4 
(3.4%) 
(3.0%) 
+0.04 
+0.03 
(2.3%) 
(2.0%) 
87 
72 
-0.6 
-0.7 
(2.9%) 
(3.5%) 
-0.06 
-0.06 
(2.0%) 
(2.4%) 
Not Known 
 
Roche 
 
Sebia Capillarys 2 
123 
288 
57 
0.0 
-0.9 
-0.4 
(5.3%) 
(4.4%) 
(2.6%) 
0.00 
-0.08 
-0.04 
(3.6%) 
(3.0%) 
(1.8%) 
14 
100 
45 
-0.8 
-0.1 
-1.4* 
(8.1%) 
(4.9%) 
(2.5%) 
-0.07 
-0.01 
-0.14 
(5.4%) 
(3.3%) 
(1.7%) 
 
Sebia Capillarys 3 
Sebia Minicap 
 
8 
10 
0.0 
-0.8 
(2.3%) 
(2.5%) 
0.00 
-0.08 
(1.6%) 
(1.7%) 
9 -1.3 (2.1%) -0.12 (1.4%) 
Siemens Advia 
Siemens DCA/Vantage 
Siemens Dimension 
15 
158 
47 
+3.5* 
+0.6 
0.0 
(4.8%) 
(3.6%) 
(4.0%) 
+0.32 
+0.06 
0.00 
(3.2%) 
(2.4%) 
(2.7%) 
 
6 
17 
 
+4.0 
+0.4 
 
(3.6%) 
(4.7%) 
 
+0.38 
+0.04 
 
(2.4%) 
(3.1%) 
 
Siemens Other 
Tosoh G7 
Tosoh G8 
Trinity Premier Hb9210 
13 
27 
234 
27 
-0.3 
+1.1 
+1.0* 
+1.2 
(4.2%) 
(5.6%) 
(2.6%) 
(3.8%) 
-0.03 
+0.10 
+0.09 
+0.10 
(2.8%) 
(3.8%) 
(1.8%) 
(2.5%) 
 
33 
85 
16 
 
-0.4 
-0.7 
-0.8 
 
(4.7%) 
(3.9%) 
(3.7%) 
 
-0.04 
-0.07 
-0.08 
 
(3.2%) 
(2.6%) 
(2.5%) 
* Significant different from target (p<0.05) 
C
lin
ic
a
l C
h
e
m
is
try
 
25  
C o n f i d e n t i a l 
 
 
 
 
 
 
 
 
524  
525  
526  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
527  
 
Table 3. Overview of Supplemental Data organized according to reporting units, matrix of the samples, and subgroups 
 
 
Reporting 
Units 
 
Matrix of Samples 
 
Subgroups 
Supplemental 
Table no. 
 
 
 
 
 
 
 
 
 
All Results 
 
 
 
 
IFCC 
 
Fresh 
Whole Blood 
Per Country 1 
Per Manufacturer (n>5) 2 
Per Manufacturer (n<6) 3 
Per Country per Manufacturer 4 
 
Lyophilized 
Hemolysate 
Per Country 5 
Per Manufacturer (n>5) 6 
Per Manufacturer (n<6) 7 
Per Country per Manufacturer 8 
 
 
 
 
NGSP 
 
Fresh 
Whole Blood 
Per Country 9 
Per Manufacturer (n>5) 10 
Per Manufacturer (n<6) 11 
Per Country per Manufacturer 12 
 
Lyophilized 
Hemolysate 
Per Country 13 
Per Manufacturer (n>5) 14 
Per Manufacturer (n<6) 15 
Per Country per Manufacturer 16 
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528  Figure Legends 
 
529  
 
 
530  Fig.1. Design of the European HbA1c Trial 
 
531  Donation (yellow) from which fresh whole blood (green) and lyophilized hemolysate 
 
532  (pink) samples are prepared and used in the respective countries (blue). Supporting 
 
533  tests (grey). Countries: Austria (AT), Belgium (BE), Switzerland (CH), Czech 
 
534  Republic (CZ), Germany (DE), Spain (ES), France (FR), Greece (GR), group of 
 
535  individual laboratories in multiple countries (I), Ireland (IE), Italy (IT), the Netherlands 
 
536  (NL), Portugal (PT), Sweden (SE), Turkey (TR), United Kingdom (UK), South Africa 
 
537  (ZA). 
 
538  
 
 
539  Fig 2. Performance per Country (A,B) and per Manufacturer (C,D) 
 
540  Mean between laboratory CV is on the horizontal axis; mean absolute bias on the 
 
541  vertical axis. The black star represents the overall performance of all laboratories. In 
 
542  Fig. A and B the circles and squares represent the countries (for abbreviations see 
 
543  legend of Fig. 1; A* is Austria without Abbott enzymatic Test users). In Fig. C and D 
 
544  the circles and squares represent the manufacturers: Abbott Architect Enzymatic test 
 
545  (A), Abbott Architect Immunochemical test (B), Abbott test not specified (C), Alere 
 
546  Afinion (D), Beckman Coulter AU systems (E), Beckman Coulter Unicell DxC 
 
547  systems (F), Bio-Rad D10 (G), Bio-Rad D100 (H), Bio-Rad Variant II (J), Medinor (K), 
 
548  Menarini-ARKRAY HA-8160 (L), Menarini-ARKRAY HA-8180 (M), not-specified 
 
549  methods (N), Roche (O), Sebia Capillarys 2 Flex Piercing (P), Sebia Capillarys 3 
 
550  Tera (Q), Sebia MiniCap (R), Siemens Advia (S), Siemens DCA/Vantage (T), 
 
551  Siemens Dimension (U), Siemens not specified (V), Tosoh G7 (W), Tosoh G8 (X), 
 
552  Trinity Biotech Premier Hb9210 (Z). The bias on the y-axis is absolute; to differentiate 
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553  between positive and negative bias, circles represent positive and squares negative 
 
554  bias. 
 
555  
 
 
556  Fig. 3. Performance per Manufacturer per Country 
 
557  Performance per manufacturer per country in lyophilized and fresh whole blood for a 
 
558  selection of major manufacturers. The black star represents the overall performance 
 
559  of all laboratories in the groups. The circles and squares show the performances per 
 
560  country within the respective manufacturer groups. The bias on the y-axis is 
 
561  absolute; to differentiate between positive and negative bias, circles represent 
 
562  positive and squares negative bias. For scaling, see legend of Fig. 2. For country 
 
563  abbreviations see legend of Fig 1. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
